Table 3.
Objective response (OR) to paclitaxel, ifosfamide, and nedaplatin (TIN) as second‐line chemotherapy in 45 patients with metastatic urothelial carcinoma, stratified by response to first‐line chemotherapy
| Response to first‐line chemotherapy | Response to TIN | |||
|---|---|---|---|---|
| n | CR (%) | PR (%) | OR (%) | |
| CR | 2 | 1 (50.0) | 1 (50.0) | 2 (100.0) |
| PR | 6 | 0 (0.0) | 4 (66.7) | 4 (66.7) |
| SD | 12 | 0 (0.0) | 2 (16.7) | 2 (16.7) |
| PD | 12 | 0 (0.0) | 4 (33.3) | 4 (33.3) |
| NE | 13 | 1 (7.7) | 5 (38.5) | 6 (46.2) |
| Total | 45 | 2 (4.4) | 16 (35.6) | 18 (40.0) |
CR, complete response; NE, not evaluable (neoadjuvant or adjuvant chemotherapy); PD, progressive disease; PR, partial response; SD, stable disease.